NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.
Publication
, Journal Article
Stevenson, J; Ettinger, DS; Wood, DE; Aisner, DL; Akerley, W; Bauman, JR; Bharat, A; Bruno, DS; Chang, JY; Chirieac, LR; DeCamp, M; Desai, A ...
Published in: J Natl Compr Canc Netw
March 2024
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2024
Volume
22
Issue
2
Start / End Page
72 / 81
Location
United States
Related Subject Headings
- Pleural Neoplasms
- Pleura
- Oncology & Carcinogenesis
- Mesothelioma, Malignant
- Mesothelioma
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Stevenson, J., Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., … Hang, L. (2024). NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024. J Natl Compr Canc Netw, 22(2), 72–81. https://doi.org/10.6004/jnccn.2024.0014
Stevenson, James, David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, et al. “NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.” J Natl Compr Canc Netw 22, no. 2 (March 2024): 72–81. https://doi.org/10.6004/jnccn.2024.0014.
Stevenson J, Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, et al. NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024. J Natl Compr Canc Netw. 2024 Mar;22(2):72–81.
Stevenson, James, et al. “NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.” J Natl Compr Canc Netw, vol. 22, no. 2, Mar. 2024, pp. 72–81. Pubmed, doi:10.6004/jnccn.2024.0014.
Stevenson J, Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai A, Dilling TJ, Dowell J, Durm GA, Garassino MC, Gettinger S, Grotz TE, Gubens MA, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Owen D, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hang L. NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024. J Natl Compr Canc Netw. 2024 Mar;22(2):72–81.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2024
Volume
22
Issue
2
Start / End Page
72 / 81
Location
United States
Related Subject Headings
- Pleural Neoplasms
- Pleura
- Oncology & Carcinogenesis
- Mesothelioma, Malignant
- Mesothelioma
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis